Boston Scientific Current Ratio 2010-2025 | BSX
Current and historical current ratio for Boston Scientific (BSX) from 2010 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Boston Scientific current ratio for the three months ending March 31, 2025 was 1.45.
| Boston Scientific Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-03-31 | $7.34B | $5.06B | 1.45 |
| 2024-12-31 | $6.92B | $6.40B | 1.08 |
| 2024-09-30 | $8.76B | $5.91B | 1.48 |
| 2024-06-30 | $8.99B | $5.58B | 1.61 |
| 2024-03-31 | $8.19B | $4.92B | 1.67 |
| 2023-12-31 | $6.51B | $4.93B | 1.32 |
| 2023-09-30 | $6.50B | $4.58B | 1.42 |
| 2023-06-30 | $5.89B | $4.56B | 1.29 |
| 2023-03-31 | $5.70B | $4.08B | 1.40 |
| 2022-12-31 | $5.76B | $3.80B | 1.52 |
| 2022-09-30 | $5.14B | $3.55B | 1.45 |
| 2022-06-30 | $5.08B | $3.88B | 1.31 |
| 2022-03-31 | $5.07B | $4.28B | 1.19 |
| 2021-12-31 | $6.32B | $4.27B | 1.48 |
| 2021-09-30 | $6.23B | $4.02B | 1.55 |
| 2021-06-30 | $6.76B | $4.07B | 1.66 |
| 2021-03-31 | $6.10B | $3.39B | 1.80 |
| 2020-12-31 | $6.69B | $3.68B | 1.82 |
| 2020-09-30 | $6.16B | $3.30B | 1.87 |
| 2020-06-30 | $5.80B | $3.11B | 1.87 |
| 2020-03-31 | $4.82B | $3.98B | 1.21 |
| 2019-12-31 | $4.70B | $4.87B | 0.97 |
| 2019-09-30 | $4.85B | $4.25B | 1.14 |
| 2019-06-30 | $6.33B | $4.85B | 1.31 |
| 2019-03-31 | $6.23B | $4.48B | 1.39 |
| 2018-12-31 | $4.00B | $5.26B | 0.76 |
| 2018-09-30 | $3.97B | $5.08B | 0.78 |
| 2018-06-30 | $3.93B | $4.75B | 0.83 |
| 2018-03-31 | $4.08B | $4.99B | 0.82 |
| 2017-12-31 | $3.82B | $5.65B | 0.68 |
| 2017-09-30 | $3.48B | $4.83B | 0.72 |
| 2017-06-30 | $3.22B | $4.30B | 0.75 |
| 2017-03-31 | $3.03B | $3.49B | 0.87 |
| 2016-12-31 | $3.24B | $3.59B | 0.90 |
| 2016-09-30 | $3.18B | $3.02B | 1.06 |
| 2016-06-30 | $3.33B | $3.18B | 1.05 |
| 2016-03-31 | $3.16B | $2.61B | 1.21 |
| 2015-12-31 | $3.47B | $2.43B | 1.43 |
| 2015-09-30 | $3.46B | $2.24B | 1.55 |
| 2015-06-30 | $3.77B | $1.94B | 1.95 |
| 2015-03-31 | $3.19B | $2.46B | 1.30 |
| 2014-12-31 | $3.61B | $2.85B | 1.27 |
| 2014-09-30 | $3.18B | $1.82B | 1.75 |
| 2014-06-30 | $3.21B | $1.77B | 1.81 |
| 2014-03-31 | $2.94B | $1.72B | 1.71 |
| 2013-12-31 | $3.01B | $1.82B | 1.65 |
| 2013-09-30 | $3.53B | $1.90B | 1.85 |
| 2013-06-30 | $3.50B | $2.48B | 1.41 |
| 2013-03-31 | $3.10B | $1.64B | 1.90 |
| 2012-12-31 | $3.02B | $1.77B | 1.71 |
| 2012-09-30 | $3.17B | $1.82B | 1.75 |
| 2012-06-30 | $3.11B | $1.79B | 1.73 |
| 2012-03-31 | $3.09B | $1.67B | 1.85 |
| 2011-12-31 | $3.11B | $1.81B | 1.72 |
| 2011-09-30 | $3.21B | $1.89B | 1.70 |
| 2011-06-30 | $3.15B | $1.89B | 1.66 |
| 2011-03-31 | $3.57B | $2.04B | 1.75 |
| 2010-12-31 | $3.62B | $2.61B | 1.39 |
| 2010-09-30 | $3.56B | $2.96B | 1.20 |
| 2010-06-30 | $3.99B | $3.72B | 1.07 |
| 2010-03-31 | $3.75B | $2.91B | 1.29 |
| 2009-12-31 | $4.60B | $3.02B | 1.52 |
| 2009-09-30 | $4.96B | $3.18B | 1.56 |
| 2009-06-30 | $4.80B | $2.75B | 1.74 |
| 2009-03-31 | $4.57B | $2.43B | 1.88 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $154.291B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $239.054B | 28.75 |
| Stryker (SYK) | United States | $149.710B | 31.30 |
| EssilorLuxottica (ESLOY) | France | $128.407B | 0.00 |
| Medtronic (MDT) | Ireland | $110.260B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.622B | 0.00 |
| Haleon (HLN) | United Kingdom | $47.216B | 26.92 |
| ResMed (RMD) | United States | $37.817B | 28.40 |
| Agilent Technologies (A) | United States | $33.696B | 21.97 |
| GE HealthCare Technologies (GEHC) | United States | $33.311B | 15.81 |
| Terumo (TRUMY) | Japan | $27.198B | 35.33 |
| Koninklijke Philips (PHG) | Netherlands | $23.033B | 16.16 |
| Insulet (PODD) | United States | $21.551B | 84.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.358B | 11.79 |
| Baxter (BAX) | United States | $15.708B | 11.73 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.095B | 0.00 |
| Demant (WILYY) | Denmark | $9.110B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.558B | 22.82 |
| Lantheus Holdings (LNTH) | United States | $5.573B | 14.06 |
| Prestige Consumer Healthcare (PBH) | United States | $4.039B | 18.04 |
| Perrigo (PRGO) | Ireland | $3.660B | 9.28 |
| Haemonetics (HAE) | United States | $3.526B | 16.06 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.280B | 27.25 |
| ICU Medical (ICUI) | United States | $3.251B | 23.97 |
| GN Store Nord (GNNDY) | Denmark | $2.346B | 19.43 |
| LeMaitre Vascular (LMAT) | United States | $1.910B | 42.70 |
| QuidelOrtho (QDEL) | United States | $1.901B | 13.07 |
| AtriCure (ATRC) | United States | $1.598B | 0.00 |
| Acuren (TIC) | United States | $1.263B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.216B | 12.34 |
| Green Thumb Industries (GTBIF) | United States | $1.111B | 25.00 |
| Neogen (NEOG) | United States | $1.057B | 13.53 |
| BioLife Solutions (BLFS) | United States | $1.015B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.003B | 12.82 |
| Kestra Medical Technologies (KMTS) | United States | $0.908B | 0.00 |
| InMode (INMD) | Israel | $0.898B | 9.05 |
| CeriBell (CBLL) | United States | $0.698B | 0.00 |
| Owens & Minor (OMI) | United States | $0.607B | 5.04 |
| Evolus (EOLS) | United States | $0.587B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.578B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.557B | 0.00 |
| Valneva SE (VALN) | France | $0.468B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.459B | 0.00 |
| Surmodics (SRDX) | United States | $0.413B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.396B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.335B | 12.32 |
| SNDL (SNDL) | Canada | $0.321B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.301B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.281B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 23.27 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.250B | 0.00 |
| ZimVie (ZIMV) | United States | $0.250B | 11.34 |
| Sanara MedTech (SMTI) | United States | $0.249B | 0.00 |
| Quanterix (QTRX) | United States | $0.241B | 0.00 |
| Brainsway (BWAY) | Israel | $0.233B | 61.65 |
| Biote (BTMD) | United States | $0.227B | 6.37 |
| Canopy Growth (CGC) | Canada | $0.226B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.220B | 65.33 |
| OraSure Technologies (OSUR) | United States | $0.215B | 0.00 |
| Omeros (OMER) | United States | $0.205B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.197B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.181B | 14.71 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Organigram Global (OGI) | Canada | $0.177B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.175B | 0.00 |
| Exagen (XGN) | United States | $0.144B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.138B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 14.81 |
| Jin Medical (ZJYL) | China | $0.108B | 0.00 |
| Veru (VERU) | United States | $0.102B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Fonar (FONR) | United States | $0.088B | 11.32 |
| Quipt Home Medical (QIPT) | United States | $0.084B | 0.00 |
| MacroGenics (MGNX) | United States | $0.083B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.078B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.075B | 0.00 |
| Zynex (ZYXI) | United States | $0.074B | 0.00 |
| Apyx Medical (APYX) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.067B | 0.00 |
| Agape ATP (ATPC) | $0.063B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.061B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 59.98 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.25 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Safety Shot (SHOT) | United States | $0.023B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Senestech (SNES) | United States | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |